A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)
This is an adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/microliter on two counts no sooner than 7 days apart in the 15 days before treatment begins.
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura
- ClinicalTrials.gov Identifier: NCT03395210
- Protocol Number: 18-048
- Principal Investigator: Jeffrey Zwicker
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required